West to Showcase New Products at Pharmapack 2020

Article

West Pharmaceutical Services will be showcasing various new pharmaceutical containment and closure offerings at Pharmapack from Feb. 5–6 in Paris, France.

West Pharmaceutical Services, an injectable drug administration company based in Exton, PA, announced it will be showcasing various new pharmaceutical containment and closure offerings at Pharmapack from Feb. 5–6 in Paris, France.

According to a company press release, the new products include:

  • AccelTRA components program. This includes two line extensions, the AccelTRA and the AccelTRA Select EU. Also to be featured will be 13-mm and 20-mm serum and lyo stoppers in eight configurations and 1–3-mL plungers for generics customers.

  • Flip-Off CCS Seal. Formulated to provide users with a ready-to-use sterile capping product, this seal maintains container closure integrity and supports a useful customer experience.

  • Ready Pack system. Developed in collaboration with Schott, this system combines West and Schott products on a small quality basis.

The company will also host two presentations during the conference. Fran DeGrazio, vice-president, Scientific Affairs and Technical Services at West, will present on “Understanding the Complexities of Delivering a Biologic Drug to the Market” during the main Pharmapack session on biologics on Feb. 6 at 10:05 a.m. CEST, and Nico Brandes, director, Market Development, Innovation, and Technology at West will host a Learning Lab session entitled, “Design with the End in Mind: Patient-Centric Innovations in Containment and Delivery,” on Feb. 6 at 11:30 a.m. CEST.

“West’s priority is to help customers simplify their journey, whether through new products or by helping mitigate risks in the drug development process to accelerate speed to market in today’s ever-evolving, complex industry and global regulatory environment,” said DeGrazio in the company press release. “We have deep knowledge of navigating the nuances of biologic drugs and delivery systems even at the earliest stages, including quality systems, design controls, and risk management frameworks. By keeping a lens on the unique interface between a drug, its primary package and device, we support our customers with smart integrated solutions from end to end that help them meet, if not exceed, industry standards.”

Source: West

 

 

Recent Videos
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content